Epigenetic dysregulation is a common feature of most cancers, often occurring directly
through alteration of epigenetic machinery. Over the last several years, a new generation of …

Acute myeloid leukemia (AML) is a hematological malignancy characterized by uncontrolled
proliferation, differentiation arrest, and accumulation of immature myeloid progenitors …

This multicenter, randomized, open-label, phase 3 trial evaluated azacitidine efficacy and
safety vs conventional care regimens (CCRs) in 488 patients age≥ 65 years with newly …

Acute myeloid leukemia (AML) is characterized by clinical and biological heterogeneity.
Despite the advances in our understanding of its pathobiology, the chemotherapy-directed …

Innate and acquired resistance towards the conventional therapeutic regimen imposes a
significant challenge for the successful management of cancer for decades. In patients with …

Acute myeloid leukaemia (AML) is a heterogeneous disease that is, in general, associated
with a very poor prognosis. Multiple cytogenetic and molecular abnormalities that …

DNA methyltransferase inhibitors (DNMTi) approved for older AML patients are clinically
tested in combination with histone deacetylase inhibitors (HDACi). The mechanism of action …

More than half of the patients with acute myeloid leukaemia (AML) are older than 60 years.
The treatment outcomes in this group remain poor with a median overall survival of< 1 year …

Most, if not all, human cancers exhibit altered epigenetic signatures that promote aberrant
gene expression that contributes to cellular transformation. Historically, attempts to …

Panobinostat, also known as Farydak®, LBH589, PNB, or panobinostat lactate, is a
hydroxamic acid that has been approved by the Food and Drug Administration (FDA) for its …